ReviewDrugs2022
Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review.
Review in Drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Age-Specific Considerations in Bronchiectasis Management: Focus on Older Adults with Emphasis on Anti-inflammatory Treatment.Drugs & aging · 2026Review
- Bronchiectasis in Older Adults: Distinctive Epidemiology, Etiology, Diagnosis, and Clinical Evolution Compared with Younger Populations.Drugs & aging · 2026Review
- Bronchiectasis in Italy: an analysis of the EMBARC registry.ERJ open research · 2026Article
- Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast.Pulmonary therapy · 2026Article
- Redox signaling in chronic airway diseases: pathogenic mechanisms and therapeutic implications.Frontiers in physiology · 2026Review
- Inhaled Corticosteroid Use and Risk ofJournal of clinical medicine · 2025Article
- Inflammatory Phenotypes of Bronchiectasis.Journal of personalized medicine · 2025Review
- Immune cell regulatory networks in chronic obstructive pulmonary disease: mechanistic analysis from innate to adaptive immunity.Frontiers in immunology · 2025Review
- Severe bronchiectasis is associated with increased carotid intima-media thickness.BMC cardiovascular disorders · 2024Article
- Exacerbations of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Hospital admission rates and related outcomes among adult Aboriginal australians with bronchiectasis - a ten-year retrospective cohort study.BMC pulmonary medicine · 2024Article
- Comorbidities in COPD: Current and Future Treatment Challenges.Journal of clinical medicine · 2024Review
- Factors influencing survival and mortality among adult Aboriginal Australians with bronchiectasis-A 10-year retrospective study.Frontiers in medicine · 2024Article
- Expert consensus on the use of oropharyngeal probiotic Bactoblis in respiratory tract infection and otitis media: available clinical evidence and recommendations for future research.Frontiers in pediatrics · 2024Article
- Brazilian Thoracic Association recommendations for the management of post-tuberculosis lung disease.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Article
- Bronchiectasis-COPD Overlap Syndrome: Role of Peripheral Eosinophil Count and Inhaled Corticosteroid Treatment.Journal of clinical medicine · 2023Article
- Management of comorbidities in difficult and severe asthma.Breathe (Sheffield, England) · 2023Review
- Inhaled Corticosteroids and Bronchiectasis: Friend or Foe?Journal of clinical medicine · 2023Article
- Bronchiectasis.Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to their potent anti-inflammatory capacity (particularly in predominantly eosinophilic inflammation) and immunosuppressive properties, inhaled corticosteroids (ICSs) are widely used in asthmatic patients and also in individuals with chronic obstructive pulmonary disease (COPD) who suffer multiple exacerbations or have peripheral eosinophilia. However, there is little evidence for their use in non-cystic fibrosis bronchiectasis (hereafter, bronchiectasis). According to data extracted from large databases of bronchiectasis in adults, ICSs are used in more than 50% of patients without any scientific evidence to justify their efficacy and contrary to the recommendations of international guidelines on bronchiectasis that generally advise against their use. Indeed, bronchiectasis is a disease with predominantly neutrophilic inflammation and a high likelihood of chronic bacterial bronchial infection. Furthermore, it is known that due to their immunosuppressive properties, ICSs can induce an increase in bacterial infections. This manuscript aims to review the basic properties of ICSs, how they impact bronchiectasis in adults, the current position of international guidelines on this treatment, and the current indications and future challenges related to ICS use in bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.